Article ; Online: Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis.
2024 Volume 43, Issue 4, Page(s) 713–721
Abstract: Background and aim: Patients with end-stage liver disease (ESLD) are susceptible to invasive pulmonary aspergillosis (IPA). This study aimed to investigate the risk factors affecting the occurrence and short-term prognosis of ESLD complicated by IPA.: ...
| Abstract | Background and aim: Patients with end-stage liver disease (ESLD) are susceptible to invasive pulmonary aspergillosis (IPA). This study aimed to investigate the risk factors affecting the occurrence and short-term prognosis of ESLD complicated by IPA. Methods: This retrospective case-control study included 110 patients with ESLD. Of them, 27 ESLD-IPA received antifungal therapy with amphotericin B (AmB); 27 AmB-free-treated ESLD-IPA patients were enrolled through 1:1 propensity score matching. Fifty-six ESLD patients with other comorbid pulmonary infections were enrolled as controls. The basic features of groups were compared, while the possible risk factors affecting the occurrence and short-term outcomes of IPA were analyzed. Results: Data analysis revealed invasive procedures, glucocorticoid exposure, and broad-spectrum antibiotic use were independent risk factors for IPA. The 54 patients with ESLD-IPA exhibited an overall treatment effectiveness and 28-d mortality rate of 50.00% and 20.37%, respectively, in whom patients treated with AmB-containing showed higher treatment efficacy than patients treated with AmB-free antifungal regimens (66.7% vs. 33.3%, respectively, χ Conclusions: Glucocorticoid exposure, invasive procedures, and broad-spectrum antibiotic exposure increased the risk of IPA in ESLD patients. AmB alone or combined with other antifungals may serve as an economical, safe, and effective treatment option for ESLD-IPA. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Antifungal Agents ; Invasive Pulmonary Aspergillosis ; Retrospective Studies ; Case-Control Studies ; End Stage Liver Disease ; Glucocorticoids ; Amphotericin B/therapeutic use ; Prognosis ; Risk Factors ; Anti-Bacterial Agents/therapeutic use | |||||
| Chemical Substances | Antifungal Agents ; Glucocorticoids ; Amphotericin B (7XU7A7DROE) ; Anti-Bacterial Agents | |||||
| Language | English | |||||
| Publishing date | 2024-02-12 | |||||
| Publishing country | Germany | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 603155-9 | |||||
| ISSN | 1435-4373 ; 0934-9723 ; 0722-2211 | |||||
| ISSN (online) | 1435-4373 | |||||
| ISSN | 0934-9723 ; 0722-2211 | |||||
| DOI | 10.1007/s10096-024-04775-1 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1732: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.